Medical affairs teams produce evidence-based, non-promotional scientific content for healthcare professionals (HCPs), while marketing teams develop engaging materials on overlapping topics such as ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

For example, if they are trained on data that reflects existing disparities in treatment or demographics, the AI could perpetuate these inequalities, leading to poorer patient outcomes. To guard ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

At Reuters Pharma USA last month, Editor in Chief Jonah Comstock caught up with John Androsavich, general manager of Gingko ...

Chris Molloy, CEO of the Medicines Discovery Catapult, one of the latest members of the UK’s Catapult network, explains why SMEs are set to power future medicines development. We are familiar ...

Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

PT: How does pharma deal with diverse geographies during launch? AH: This is difficult! Local and national reimbursement environments vary significantly by country and many will reference ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

It is important to empower new entrants into the business. With businesses looking to build up talent pipelines and a rise in employer demand predicted, entrusting new talent with responsibility ...